About Sagimet Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://sagimet.com/
Frequently Asked Questions
What is the 52-week range for SGMT?
The 52-week high is $11.449 and the 52-week low is $4.5.
What is the P/E ratio for SGMT?
The P/E ratio data is currently unavailable.
What is the dividend yield for SGMT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -31.96%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.65.
Analyst Recommendation Trends
Wall Street analyst consensus for SGMT over the last few months:
Latest SGMT News
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China. The company also outlined plans fo
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S.
Sector Update: Healthcare Stocks Softer Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares rose more than 12% in pre-market trading on Wednesday following the release of 52-week results from license partner Ascletis’ Phase 3 open-label extension trial evaluating denifanstat in patients with moderate to severe acne. The trial reported a 57% treatment success rate after 52 weeks of denifanstat treatment, alongside a 72% reduction in total lesions and a 77% reduction in inflammatory lesions.
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patientsDenifanstat showed progressive and sustained improvements across all efficacy endpoints in the OLE, including Investigator's Global Assessment (IGA) success with a response rate of 57%, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-tolerated, with no adverse event-related perman
Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit
Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded warrants to purchase
Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the "ATM Prospectus Supplement") related to the Company’s Series A common stock, par value $0.0001 per share (the
Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight
The acne vulgaris market is expected to progress steadily, supported by an increasing number of emerging therapies advancing through clinical development. Key players, including Ascletis Pharma and Sagimet Biosciences with Denifanstat (ASC40), and AOB Pharma with B244, are demonstrating a strong commitment to addressing unmet needs in acne treatment through continued efforts to develop innovative therapeutic options.New York, USA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Acne Vulgaris Market Set for S
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, September 30, 2026, at 1:00 PM ET featuring Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society. To register, click here. Dr. Harper will jo
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-14 | Kemble George | -24,369 | - | - |
| 2026-08-14 | Kemble George | -326,618 | - | - |
| 2026-08-14 | Kemble George | -350,987 | $10.2328 | $3,591,580 |
| 2026-08-14 | Kemble George | +24,369 | $6.36 | $154,987 |
| 2026-08-14 | Kemble George | +326,618 | $6.36 | $2,077,290 |
| 2026-08-11 | Kemble George | -10,455 | - | - |
| 2026-08-11 | Kemble George | -9,751 | - | - |
| 2026-08-11 | Kemble George | -20,206 | $9.9548 | $201,147 |
| 2026-08-11 | Kemble George | +10,455 | $6.36 | $66,494 |
| 2026-08-11 | Kemble George | +9,751 | $6.36 | $62,016 |
| 2026-07-20 | Happel David | -64,051 | $7.7605 | $497,068 |
| 2026-07-20 | Rozek Elizabeth | -10,545 | $7.7603 | $81,832 |
| 2026-07-20 | Kemble George | -18,844 | $7.4575 | $140,529 |
| 2026-06-12 | Hoelscher Paul W. | +39,567 | - | - |
| 2026-06-12 | Jarrett Jennifer | +39,567 | - | - |
| 2026-06-12 | Kemble George | +39,567 | - | - |
| 2026-06-12 | Phillips Anne M. | +39,567 | - | - |
| 2026-06-12 | GRAMMER ELIZABETH A | +39,567 | - | - |
| 2026-06-12 | SEIDENBERG BETH C | +39,567 | - | - |
| 2026-05-28 | Chauche Thierry | +50,000 | - | - |
| 2026-05-28 | Grauer Andreas | +35,000 | - | - |
| 2026-05-28 | Rozek Elizabeth | +100,000 | - | - |
| 2026-05-28 | Happel David | +300,000 | - | - |
| 2026-04-20 | Grauer Andreas | +264,759 | - | - |
| 2026-02-19 | Rozek Elizabeth | +88,000 | - | - |
| 2026-02-19 | Rozek Elizabeth | +44,000 | - | - |
| 2026-02-19 | Martins Eduardo Bruno | +88,000 | - | - |
| 2026-02-19 | Martins Eduardo Bruno | +44,000 | - | - |
| 2026-02-19 | Happel David | +256,000 | - | - |
| 2026-02-19 | Happel David | +128,000 | - | - |
| 2026-02-19 | Chauche Thierry | +88,000 | - | - |
| 2026-02-19 | Chauche Thierry | +44,000 | - | - |
| 2026-02-10 | Happel David | -12,101 | $5.3603 | $64,865 |
| 2026-02-10 | Chauche Thierry | -1,312 | $5.3603 | $7,033 |
| 2026-02-10 | Martins Eduardo Bruno | -3,640 | $5.3602 | $19,511 |
| 2026-02-10 | Rozek Elizabeth | -2,622 | $5.3602 | $14,054 |
| 2025-11-20 | Kemble George | -37,688 | $7.6942 | $289,979 |
| 2025-11-04 | Rozek Elizabeth | +13,367 | - | - |
| 2025-11-04 | Rozek Elizabeth | +9,855 | - | - |